LYFGENIA
Drug
bluebird bio, Inc.
Total Payments
$1.8M
Transactions
239
Doctors
96
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $346,804 | 131 | 85 |
| 2023 | $1.4M | 108 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 96 | 91.4% |
| Consulting Fee | $131,459 | 39 | 7.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,250 | 1 | 0.9% |
| Food and Beverage | $6,094 | 103 | 0.3% |
Payments by Type
Research
$1.6M
96 transactions
General
$153,803
143 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease | bluebird bio, Inc. | $862,973 | 0 |
| Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector | bluebird bio, Inc. | $465,139 | 0 |
| SRA for HGB 206, LTF 307 | bluebird bio, Inc. | $200,000 | 0 |
| A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease | bluebird bio, Inc. | $78,103 | 0 |
| Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector | bluebird bio, Inc. | $23,870 | 0 |
Top Doctors Receiving Payments for LYFGENIA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Northbrook, IL | $1.6M | 97 |
| , MD, MS | Pediatric Hematology-Oncology | La Jolla, CA | $84,150 | 10 |
| , MD, PHD | Medical Oncology | Boston, MA | $8,160 | 1 |
| , M.D | Diagnostic Radiology | Burnsville, MN | $7,278 | 6 |
| , MD | Hematology | Boston, MA | $6,300 | 1 |
| , MD | Medical Oncology | New York, NY | $4,454 | 6 |
| , MD | Hematology & Oncology | Farmington, CT | $3,740 | 1 |
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $3,060 | 1 |
| , MD | Internal Medicine | Durham, NC | $1,800 | 1 |
| John Zaia | — | Duarte, CA | $1,650 | 1 |
| , M.D | Pediatric Hematology-Oncology | Durham, NC | $1,470 | 1 |
| , MD | Hematology | Charlotte, NC | $1,470 | 1 |
| , M.D | Pediatrics | Royal Oak, MI | $1,240 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $1,238 | 2 |
| , M.D | Pediatric Hematology-Oncology | Chicago, IL | $1,220 | 1 |
| , M.D | Pediatric Hematology-Oncology | San Diego, CA | $1,190 | 1 |
| , M.D | Pediatric Hematology-Oncology | New Hyde Park, NY | $980.00 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Chicago, IL | $900.00 | 1 |
| , D.O | Student in an Organized Health Care Education/Training Program | Houston, TX | $740.00 | 1 |
| , M.D | Medical Oncology | Tampa, FL | $523.77 | 7 |
| , CPNP | Pediatrics | Atlanta, GA | $440.00 | 1 |
| , MD | Hematology & Oncology | Gainesville, FL | $358.15 | 4 |
| , MD | Hematology & Oncology | Tampa, FL | $313.11 | 3 |
| , MD | Hematology & Oncology | Doral, FL | $255.31 | 3 |
| , AGPCNP | Nurse Practitioner | Tampa, FL | $178.90 | 3 |
Ad
Manufacturing Companies
- bluebird bio, Inc. $1.8M
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 96
- Transactions 239
About LYFGENIA
LYFGENIA is a drug associated with $1.8M in payments to 96 healthcare providers, recorded across 239 transactions in the CMS Open Payments database. The primary manufacturer is bluebird bio, Inc..
Payment data is available from 2023 to 2024. In 2024, $346,804 was paid across 131 transactions to 85 doctors.
The most common payment nature for LYFGENIA is "Unspecified" ($1.6M, 91.4% of total).
LYFGENIA is associated with 5 research studies, including "A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease" ($862,973).